Analyst Conference Summaries

Biotechnology Investor Aids

GlycoMimetics
GLYC

conference date: November 8, 2017 @ 5:30 AM Pacific Time

GlycoMimetics Remains Undervalued After Leukemia Data Release [June 14, 2017 at Seeking Alpha]

AML Therapies: Seattle Genetics vs. GlycoMimetics [July 15, 2016 at Seeking Alpha]

GlycoMimetics: Undercovered with Catalysts Coming [June 9, 2016 at Seeking Alpha]
GlycoMimetics GMI-1271 Effective in Phase I Leukemia Trial [May 19, 2016]
GlycoMimetics Novel Therapeutic Approach [February 5, 2016 at Seeking Alpha]
I Buy GlycoMimetics [April 6, 2015 at Dissecting the Bull]

Note: GlycoMimetics is not currently hosting analyst calls to discuss quarterly results.

Analyst Call Notes by William P. Meyers
2017
 
May 18, 2017
 
 Nov. 8, 2017
 
2016
05/04/2016
08/04/2016
11/04/2016
 03/01/2017
2015
tba
8/6/2015
11/12/2015 
2/29/2016

GlycoMimetics and Pfizer Initiate Phase 3 Rivipansel Trial [June 23, 2015]
FDA Grants Orphan Drug Status to GMI-1271 [May 14, 2015]

GlycoMimetics (GLYC) is a clinical-stage developer of glycobiology based therapies.

GlycoMimetics web site


 

Search

More Analyst Conference Notes:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2017 William P. Meyers